Patient-Derived Organoid Modeling of Glypican-3 CAR-T Responses in Hepatocellular Carcinoma
Open Access
Abstract
Glypican-3 (GPC3)-targeted chimeric antigen receptor T (CAR-T) cell therapy is a promising approach for hepatocellular carcinoma (HCC), but marked interpatient variability and antigen heterogeneity limit its broader application. Here, we established a patient-derived organoid (PDO)-based platform to functionally evaluate autologous GPC3-targeted CAR-T cell activity in HCC. HCC PDOs preserved key histologic features and heterogeneous GPC3 expression patterns of the original tumors. In co-culture assays, CAR-T cell cytotoxicity was associated with GPC3 expression levels and was accompanied by IFN-γ and IL-2 release, supporting the feasibility of using PDOs for functional assessment of CAR-T cell sensitivity. We further found that matrix conditions strongly influenced organoid architecture, viral transduction, CAR-T cell infiltration, and killing efficiency, with lower Matrigel concentrations providing a more permissive setting for functional assessment. Importantly, in GPC3-low PDOs, pretreatment with the DNA methyltransferase inhibitor 5-azacytidine (5-AZA) reduced DNA methyltransferase 3 alpha (DNMT3A) expression, increased surface GPC3 expression, and significantly enhanced CAR-T-mediated cytotoxicity. Together, these findings provide proof-of-concept evidence supporting the use of HCC PDOs as a patient-derived platform for modeling selected determinants of GPC3-targeted CAR-T cell activity and for exploring combination strategies to improve therapeutic efficacy.Keywords
Funding Information
- National Natural Science Foundation of China (82272920)
- State Key Laboratory of Systems Medicine for Cancer (zz-RCPY-25-17)
- State Key Laboratory of Systems Medicine for Cancer (zz-RCPY-26-13)
This publication has 34 references indexed in Scilit:
- Safety and efficacy of JWATM204, a novel Glypican-3 (GPC3)-targeted CAR T cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation studyCancer Pathogenesis and Therapy, 2025
- Novel Prognostic Scoring Systems for Severe CRS after Anti-CD19 CAR-T-Cells in Acute B-Lymphoblastic LeukemiaCurrent Medical Science, 2025
- Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapyCell Stem Cell, 2024
- Heat-inducible CAR-T overcomes adverse mechanical tumor microenvironment in a 3D bioprinted glioblastoma modelMaterials Today Bio, 2024
- RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trialeClinicalMedicine, 2023
- Hepatocellular carcinomaThe Lancet, 2022
- Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal CancerCell Stem Cell, 2020
- A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral HeterogeneityCell, 2019
- Integrated Proteogenomic Characterization of HBV-Related Hepatocellular CarcinomaCell, 2019
- Organoid Models of Human Liver Cancers Derived from Tumor Needle BiopsiesCell Reports, 2018